Annals of Indian Psychiatry
2025
T. V. Pavan Kumar, Divya Bolla, Raj Kiran Donthu et al.
Abstract Depression is the leading cause of suicide, and antidepressants and modified electroconvulsive therapy (mECT) are the preferred treatment modalities. Ketamine is an established anesthetic agent and evidence for its use in depression is evolving. Here, we discuss the experience of treating severe depression with intravenous (IV) ketamine. A patient in his mid-forties presented with a...
International Review of Psychiatry
2025
Iury P A Magalhães, Daniel N. Lopes, Isabel Amato et al.
Major depressive disorder (MDD) significantly impairs adolescents' development, with increasing rates of treatment resistance and suicide risk. Ketamine has emerged as a promising, rapid-acting antidepressant in adults, but its efficacy and safety in adolescents remain unclear. This systematic review and meta-analysis aimed to evaluate short-term outcomes of ketamine administration in youth...
Case Reports in Critical Care
2025
J. Finsterer
Methemoglobinemia is defined as an increase in methemoglobin of > 2% of hemoglobin. Ketamine is increasingly used for severe depression. To our knowledge, a patient with mitochondrial encephalopathy, lactic acidosis and stroke‐like episodes (MELAS) who died suddenly and unexpectedly 1–12 h after ketamine infusion with high postmortem methemoglobin has not yet been reported. The patient was a...
Neuromethods
2025
Naji Alnagger, Paolo Cardone, Javier Montupil et al.
AbstractKetamine is a versatile N-methyl-D-aspartate (NMDA)-antagonist used in various clinical settings. Ketamine dose-dependently induces psychoactive effects: at low, anti-hyperalgesic doses, these are minor or not detectable, but at subanesthetic doses, they may include dissociative, psychotomimetic, and psychedelic events. At an anesthetic dose, ketamine leads to a state of “(full)...
Нейрохимия / Neurochemical Journal
2025
U. S. Drozd
The hippocampus is one of the brain structures whose functions and morphology are impaired in depression. The fast-acting antidepressant ketamine reverses these impairments, but the mechanisms of its action are still not fully understood. Optogenetic stimulation of glutamatergic neurons in the CA1 region of the dorsal hippocampus of rats with the preliminary introduction of vectors expressing...
Frontiers in Psychiatry
2025
Congyi Li, Zhihui Wang, Xinman Ye et al.
Clinical and preclinical studies increasingly support the antidepressant potential of several anesthetic agents, including ketamine, propofol, nitrous oxide (N2O), sevoflurane, and isoflurane. Their therapeutic effects appear to arise from the regulation of multiple interconnected systems: modulation of glutamatergic and GABAergic signaling, interaction with monoaminergic neurotransmitters...
Journal of the American Board of Family Medicine : JABFM
2025
Annie Huang, Jennifer L Fernandez Vasquez, Catherine A Yeager
If available in one's practice area, augmenting current medication therapy with esketamine results in greater rates of remission for treatment resistant depression as compared with quetiapine1.
The American Journal of Bioethics
2025
Zachary J Verne, Natalie Gukasyan, Jeffrey S Zabinski
2 citations
In “Distinctive but not Exceptional: The Risks of Psychedelic Ethical Exceptionalism,” Cheung et al. (2025) elaborate the ways that psychedelics share individual ethical considerations with those o...
Frontiers in Psychiatry
2025
Alexandre Fraichot, Sophie Favre, Hélène Richard-Lepouriel
1 citation
Intranasal Esketamine is an effective rapid-acting antidepressant currently used to treat treatment-resistant depression. Artificial intelligence is another emerging tool in medicine, but little is known about the effectiveness of combining these innovations in psychiatry. This case report presents the outcome of a 37-year-old patient who received intranasal Esketamine treatment (84 mg) and...
Frontiers in Psychiatry
2025
Miriam Olivola, Filippo Mazzoni, Barbara Tarantino et al.
7 citations
Treatment-Resistant Depression (TRD) remains a major challenge in the management of Major Depressive Disorder (MDD). Esketamine, the S-enantiomer of ketamine and a glutamatergic modulator, was approved by the FDA and EMA for TRD in 2019. Beyond its rapid antidepressant effects, esketamine may enhance neuroplasticity, facilitating the reconnection with emotional and cognitive processes,...
Bipolar Disorder
2025
Breno Souza-Marques, Ana Teresa Caliman-Fontes, Gustavo C. Leal et al.
Despite the availability of many treatment options, several individuals with bipolar disorders experience persistent symptoms, necessitating the exploration of novel therapeutic approaches. In recent years, there has been a growing interest in repurposing drugs of abuse, such as stimulants, ketamine, and psychedelics, for the treatment of bipolar disorders. While some of these drugs have...
Ketamine
2025
Pouya Movahed Rad, Akihiro Takamiya
Depression is a debilitating psychiatric disorder. Electroconvulsive therapy (ECT) and ketamine are effective treatments for severe depression, but target populations may differ. Systematic reviews on the few available trials show higher remission rates with ECT than with ketamine. Nonetheless, ketamine’s rapid onset of action is comparable to ECT but with less cognitive adverse effects. This...
Ketamine
2025
Katarina Savić Vujović, Ana Jotić, Branislava Medić et al.
1 citation
Substance use disorders (SUDs), including alcohol, opioid, and cocaine dependencies, present significant challenges in public health. Current treatment modalities often face limitations in efficacy and accessibility, necessitating exploration of novel therapeutic approaches. Ketamine, originally recognized for its anesthetic properties, has garnered attention for its potential in treating SUDs...
Ketamine
2025
Jose Eduardo Guimaraes Pereira, Carlos Darcy Alves Bersot, Thiago Ramos Grigio et al.
1 citation
Neuropathic pain (NP) is a frequently undertreated component of chronic pain, posing challenges due to its complexity. This has led to interest in N-methyl-D-aspartate receptor (NMDAR) antagonists like ketamine. NP is linked to maladaptive processes, such as NMDAR-related windup and sensitization. While results from ketamine trials on chronic NP have been inconsistent, perioperative use has...
Ketamine
2025
Carson Chrenek, Jennifer Swainson
Although both intranasal esketamine and intravenous ketamine have proven efficacy and tolerability in treatment-resistant depression (TRD), patient access to these treatments is often limited due to cost, availability, and/or monitoring requirements. This article is intended to provide a synthesis of the current literature with regard to the pharmacologic use of ketamine in TRD and describe its...
Imaging Neuroscience
2025
Brandon Taraku, Jason S Nomi, Artemis Zavaliangos-Petropulu et al.
Ketamine produces fast-acting antidepressant effects in treatment-resistant depression (TRD). Prior studies have shown altered functional dynamics between brain networks in major depression. We thus sought to determine whether functional brain network dynamics are modulated by ketamine therapy in TRD. Participants with TRD (n = 58, mean age = 40.7 years, female = 48.3%) completed resting-state...
Current Addiction Reports
2025
Anahita Bassir Nia, Yalda Farahmand, Garret Griffith et al.
Despite national efforts to curb the opioid crisis, the clinical and societal challenges continue to grow. FDA-approved medications for opioid use disorder (OUD) are effective but are associated with high rates of treatment discontinuation and relapse. A collection of agents with acute effects on consciousness, collectively (if variably) categorized as 'psychedelics', have emerged as potential...
Current Addiction Reports
2025
Nina Abukahok, Nicole D. Fitzgerald, Joseph J Palamar
Tusi, also known as "pink cocaine," has emerged across nightlife scenes in Latin America, Europe, Australia, and the United States (US). Tusi is typically a drug mixture containing ketamine and 3,4-methylenedioxymethamphetamine (MDMA). Due to tusi's inconsistent chemical makeup, surveillance and harm reduction efforts have proven difficult for researchers and consumers alike. This review...
Frontiers in Neuroscience
2025
Antonio Inserra, Colin J. Murray, Antonella Campanale et al.
Emerging evidence indicates that rapid-acting antidepressants (RAADs)-including ketamine and serotonergic psychedelics- may affect myelin homeostasis, aside from producing fast-onset, sustained improvements in several psychiatric disorders. A systematic search of PubMed (MEDLINE), Web of Science, Europe PMC, Directory of Open Access Journals (DOAJ), and Google Scholar was conducted up to...
Frontiers in Pain Research
2025
Shahar Almog, Michelle Weiner, Jessica N Howarth et al.
Chronic pain is an individual experience with physical and psychological dimensions. Ketamine is used in sub-anesthetic doses to treat chronic pain. We describe a proposed multidisciplinary approach with combined treatment of low-dose ketamine and pain-focused psychological and somatic therapies to benefit quality of life of disabled chronic pain patients. Beyond pain reduction, within the...